Male and
female sexual dysfunction: Blockbuster indication for multiple pharmaco
E Sussex, UK --- 3rd
September,
2002 ---
In March, 1998, Pfizer launched
sildenafil (Viagra) for the treatment of erectile dysfunction. This move
had an explosive effect on Pfizer's financial figures. More generally,
this pharmaceutical milestone changed public awareness of erectile
dysfunction and boosted basic research activity relating to improved
understanding and treatment of this problem. Just over 4 years later LeadDiscovery
has produced a state of the art analysis of sexual dysfunction. Despite
the success of sildenafil, blockbuster opportunities still exist, both for
improved treatment of erectile dysfunction using 2nd generation PDE5
inhibitors or molecules directed towards other pathophysiological targets,
and for the treatment of the largely ignored area of female sexual
dysfunction. Sildenafil was originally developed for the treatment of
cardiovascular disorders until serendipity precipitated one of the most
well known examples of indication-switching. This report analyzes both the
science and the pharmaceutical activity surrounding male and female sexual
dysfunction, focusing on other opportunities for indication-switching as
well as novel pharmacological targets. In short this report will provide
researchers and business development personnel with one of the most up to
date and informative analyses of this blockbuster producing therapeutic
area.
LeadDiscovery
has produced one of the most up to date and comprehensive reviews of
sexual dysfunction. This state of the art report analyses pharmaceutical
opportunities, as well as current and future drug development strategies
relating to this field. In short this dossier offers a "one stop
shop" for personnel involved in the selection, development and
commercialization of novel therapeutics.
Dossier
highlights:
- 22,000 words (approx)
- One of the most comprehensive state of the art reviews of sexual
dysfunction research published to date
- Proof of concept surrounding candidate targets for the treatment of
sexual dysfunction
- Sexual dysfunction incidence and market valuation
- Identification of development activity surrounding sexual dysfunction
- Profiles on over 35 drugs in development or on the market for sexual
dysfunction
- Identification of key patents relating to advances in sexual dysfunction
- Identification of industrial field leaders
- Strategic Analysis: Proposed choice of targets
- Price $499
Target
Audience: Research or Licensing
personnel from companies with a focus on Sexual Dysfunction;
Cardiovascular Disorders; Smooth muscle; Rho-A/Rho kinase; Nitric Oxide;
Phosphodiesterases; Prostaglandins; VIP; Adenosine/Purine; Adrenoceptors;
Endothelin; Angiotensin; Serotonin; Oxytocin; Dopamine; Drug Discovery;
Lead Identification; Combinatorial or Other Chemistry; Academic personnel
wishing to commercially develop their research in these fields
To purchase this dossier
online - click here!
